Nathan B Fountain Insider Profile
4 Followers
Nathan B Fountain, Director at Acumen Pharmaceuticals, holds 48.15K shares in Acumen Pharmaceuticals (Ticker: ABOS). Most recently, Nathan B Fountain Sold 6,400 shares of Acumen Pharmaceuticals on Jun 10, 2026 for an estimated value of $14.27K.
Nathan B Fountain Acumen Pharmaceuticals (ABOS)Director
Acumen Pharmaceuticals (ABOS)
Director
Ranked #81,942 out of 109,193 Corporate Insiders
Profitable Transactions
0 out of 2 Profitable Transactions
Average Return
-33.10%
Average return per transaction
Time Frame
Compare to
Insider Holdings
100.00%
A breakdown of Nathan B Fountain's holdings
Insider Roles
Director
Roles that Nathan B Fountain holds in companies
Most Profitable Insider Trade
The most profitable trade made by Nathan B Fountain
Nathan B Fountain's Trading History
List of latest transactions for each holding click on a transaction to see Nathan B Fountain's performance on stock
You May Also Like
Nathan B Fountain insider profile FAQ
What is the percentage of profitable transactions made by Nathan B Fountain?
The percentage of profitable transactions made by Nathan B Fountain is 0%.
What is the average return per transaction made by Nathan B Fountain?
The average return per transaction made by Nathan B Fountain is -33.10%.
What stocks does Nathan B Fountain hold?
Nathan B Fountain holds: ABOS stocks.
What was Nathan B Fountain’s latest transaction?
Nathan B Fountain latest transaction was an Informative Sell of $14.27K.
What was Nathan B Fountain's most profitable transaction?
Nathan B Fountain’s most profitable transaction was an Informative Sell of ABOS stock on June 10, 2026. The return on the trade was 0.00%.
What is Nathan B Fountain's role in Acumen Pharmaceuticals?
Nathan B Fountain's role in Acumen Pharmaceuticals is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.